Keywords: guilford, hit, fda, says, new, gliadel, use
Guilford hit as FDA says no to new Gliadel use
Article | 01 April 2002
Guilford Pharmaceuticals of the USA has had its application to extendthe indications for its brain cancer treatment Gliadel Wafer (polifeprosan 20 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
